L. Mary Smith - 04 Jan 2024 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)

Role
Chief Development Officer
Signature
/s/ Francis I. Perier, Jr. as Attorney-in Fact
Issuer symbol
SWTX
Transactions as of
04 Jan 2024
Net transactions value
-$230,207
Form type
4
Filing time
08 Jan 2024, 21:13:06 UTC
Previous filing
05 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SWTX Common Stock Award $0 +21,156 +9.7% $0.000000 239,095 04 Jan 2024 Direct F1
transaction SWTX Common Stock Tax liability $83,398 -2,197 -0.92% $37.96 236,898 05 Jan 2024 Direct F2
transaction SWTX Common Stock Tax liability $146,809 -3,535 -1.5% $41.53 233,363 08 Jan 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SWTX Stock Option (Right to Buy) Award $0 +60,000 $0.000000 60,000 04 Jan 2024 Common Stock 60,000 $38.40 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date.
F2 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person.
F3 This option shall vest in forty-eight (48) equal monthly installments following January 4, 2024, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date.